


# BONE CARE FOR THE POSTMENOPAUSAL WOMAN



# TABLE OF CONTENTS

▪ Foreword	3
▪ Why bone health matters	4
▪ Postmenopausal women are at greatest risk	9
▪ How to reduce osteoporosis and fracture risk	10
▪ Individual risk factors	16
▪ Take action for a break-free future	18
▪ Importance of adhering to treatment	24
▪ References	25



## WHAT IS OSTEOPOROSIS?

Osteoporosis is a disease characterized by low bone mass and deterioration in the microarchitecture of bone tissue, leading to an increased risk of fracture. Osteoporosis occurs when the bone mass decreases more quickly than the body can replace it, leading to a net loss of bone strength. As a result the skeleton becomes fragile, so that even a slight bump or fall can lead to a broken bone, (referred to as a fragility fracture). Osteoporosis has no signs or symptoms until a fracture occurs – this is why it is often called a ‘silent disease’.

Osteoporosis affects all bones in the body; however, fractures occur most frequently in the vertebrae (spine), wrist and hip. Osteoporotic fractures of the pelvis, upper arm and lower leg

are also common. Osteoporosis itself is not painful but the broken bones can result in severe pain, significant disability and even mortality. Both hip and spine fractures are also associated with a higher risk of death - 20% of those who suffer a hip fracture die within 6 months after the fracture.

### A COMMON DISEASE

It is estimated that worldwide an osteoporotic fracture occurs every three seconds. At 50 years of age, one in three women and one in five men will suffer a fracture in their remaining lifetime. For women, the risk of hip fracture is higher than the risk of breast, ovarian and uterine cancer combined. For men, the risk is higher than the risk for prostate cancer.

Approximately 50% of people with one osteoporotic fracture will have another, with the risk of new fractures rising exponentially with each fracture.

### A GROWING PUBLIC HEALTH PROBLEM

The risk of sustaining a fracture increases exponentially with age due not only to the decrease in bone mineral density, but also due to the increased rate of falls among the elderly. The elderly represent the fastest growing segment of the population. Thus, as life expectancy increases for the majority of the world's population, the financial and human costs associated with osteoporotic fractures will increase dramatically unless preventive action is taken.



# FOREWORD

## BONE HEALTH MATTERS TO WOMEN AND THEIR FAMILIES

Postmenopausal women throughout the world are facing an ever increasing burden of responsibilities; as caregivers to the young and old, bread winners preparing for retirement and contributors to the welfare of the communities in which they live. Another, more insidious, burden is being imposed upon mothers and grandmothers, sisters and aunts, and wives and partners. A burden that is becoming ever more prevalent, on every continent, amongst hundreds of millions of older women, right now. The burden in question is osteoporosis, the most common bone disease. Osteoporosis, quite literally, can shatter women's lives.

One in three women over the age of 50 will suffer a fracture caused by osteoporosis. Every reader will know a family member or friend who has suffered an osteoporotic fracture; a 55 year old sister who slipped on the ice and broke her wrist, a 65 year old mother - who has been losing height - who suffered an excruciating vertebral crush fracture whilst lifting a box of books, or a 78 year old grandmother who tripped over a telephone cable in the night and broke her hip. All of these women's lives will be seriously affected by these injuries.

Because osteoporosis is so common, every single woman alive today must come to recognise that bone health really matters to them. This report describes the key actions women can take, both before and after the menopause, to minimise their risk of suffering debilitating and painful fractures. Postmenopausal women provide the back-bone to families throughout the world; maintaining a strong skeleton will enable them to continue to do so.

## BONE HEALTH MATTERS TO HEALTHCARE PROFESSIONALS AND SYSTEMS

During the next two decades, almost half a billion people will reach



## Bess Dawson-Hughes

Professor of Medicine, Tufts University

Director Bone Metabolism Laboratory at the Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Boston, MA, USA



## Ghada El-Hajj Fuleihan

Professor of Medicine, Director of the Calcium Metabolism and Osteoporosis Program

Director, WHO Collaborating Center for Metabolic Bone Disorders, at the American University of Beirut (AUB) Medical Center, Beirut, Lebanon



## Patricia Clark

Professor of Clinical Epidemiology at the Faculty of Medicine of the National University of Mexico (UNAM)

Head of the Clinical Epidemiology Unit, Hospital Infantil de Mexico

retirement age. As this demographic shift ensues, the demands placed upon our healthcare systems, and upon the professionals who provide care within them, will be manifest on an unprecedented scale. Crucially, clinicians throughout the world know that osteoporotic fractures are amongst the most preventable outcomes of all chronic disease.

A clear consensus has emerged amongst osteoporosis experts, geriatricians, orthopaedic surgeons and other specialties that a systematic approach to fracture prevention must be implemented on a global scale. Leading professional organisations all advocate that when postmenopausal women suffer an osteoporotic fracture, we should always respond to the first fracture to prevent the second and subsequent fractures. With the advent of fracture risk assessment calculators, doctors now have the tools to go further, and systematically identify those individuals who have not fractured yet, but are at considerably increased risk of doing so in the near future. Bone health matters to healthcare professionals

because they have the expertise, and desire, to prevent their patients from suffering fractures.

## BONE HEALTH MATTERS TO POLICYMAKERS AND THEIR GOVERNMENTS

As our population ages, policymakers are faced with an overwhelming array of competing priorities for finite healthcare resources. The key issue for policymakers to recognise is that osteoporosis is a condition where better care translates to better outcomes and significantly reduced costs. If the right evidence-based policies, reimbursement criteria and implementation strategies are in place, a substantial body of evidence demonstrates that fracture incidence will be reduced, and the costs associated with fracture care avoided. Bone health matters to policymakers, because if it doesn't, the costs of fracture care will simply continue to escalate, and consume budgets that will be needed to cope with the tsunamis of need fuelled by retirement of the baby boomers.

# WHY BONE HEALTH MATTERS

## WOMEN ARE THE BACK-BONE OF FAMILIES THROUGHOUT THE WORLD

In all countries and all cultures, women play a vital role in our main social institution, the family. As the world's population ages, the demands placed upon older women in particular are set to increase. The expression 'sandwich generation' has come into common parlance to describe those people who care for their ageing parents while supporting their own children. Indeed, the notion of a 'club sandwich generation' has been coined to describe those playing a supporting role simultaneously to ageing parents, adult children and

grandchildren. A growing body of evidence documents the prevalence and impact of care giving on older women in many countries and in a range of circumstances:

- **Australia**  
A quarter of women aged 45-64 years are carers, of which 7% are primary carers<sup>1</sup>.
- **Brazil**  
Women comprised 78% of family caregivers of elderly patients on haemodialysis and peritoneal dialysis in a Brazilian study on the impact of caring on quality of life of carers<sup>2</sup>.

- **Canada**  
Amongst the 1.7 million Canadian adults aged 45-64 who provide informal care to seniors, women dedicate twice as much time to carer tasks as men<sup>3</sup>.
- **Korea**  
On account of limited institutional provision of care services and facilities, in a study in Kwangju, South Korea, 62% of care givers were women<sup>4</sup>.
- **Mexico**  
Women have been documented to play the major care giving role in many situations, including care giving for children with cerebral



palsy<sup>5</sup>, for geriatric patients<sup>6</sup> and for cancer patients<sup>7</sup>.

- **Spain**  
Seventy percent of Spanish women over the age of 65 care for their grandchildren and 22% of them do so every day<sup>8</sup>.
- **Chinese Taipei**  
The cultural norm in Chinese Taipei is to care for family members who are disabled or ill<sup>9</sup>. A study of caregivers of persons with stroke or Alzheimer's disease reported that 75% were women aged 52 years on average<sup>10</sup>.
- **United Kingdom**  
About 25% of women aged 50-59 years in Britain provide some unpaid care<sup>11</sup>.

- **USA**  
In the United States, 75% of caregivers are women<sup>12</sup>. Forty three percent of carers are at least 50 years of age and 61% of family caregivers are women<sup>13</sup>.

### THE SOCIO-ECONOMIC IMPACT OF FRAGILITY FRACTURES


Osteoporosis is the most common bone disease and is manifest in the form of fragility fractures, also referred to as low or minimal trauma fractures. Fragility fractures usually occur as a result of a fall from standing height and are very common; 1 in 3 women over 50 years of age will suffer one<sup>15,16</sup>, as will 1 in 5 men<sup>17</sup>. Worldwide, during the year 2000, there were an estimated 9 million new fragility fractures, of which 1.6 million were

at the hip, 1.7 million at the wrist, 0.7 million at the humerus and 1.4 million symptomatic vertebral fractures<sup>18</sup>. Overall, 61% of fractures occurred in women, including 70% of hip fractures.

In recent years the International Osteoporosis Foundation (IOF) has conducted a series of regional audits to ascertain the impact that osteoporosis is having currently – and will have in the future - upon older people and healthcare systems worldwide. These data, in addition to major studies conducted in North America, reveal the immense and growing burden of osteoporosis and fractures in all regions of the world on the map overleaf.

To better understand the challenges to the health and well-being of women in Mexico, it is important to acknowledge that the family is considered the most important value in Mexican culture, and that the woman is the essential unifying element within the family. Within the family, women play the most significant role as socialization agent and caregiver.<sup>14</sup>





**North America** As recently highlighted by the 2Million2Many Campaign of the U.S. National Bone Health Alliance<sup>26</sup>, an evaluation of the incidence and costs of osteoporosis for the period 2005-2025 concluded that 2 million fragility fractures occur annually in the United States<sup>27</sup>. The proportion of fractures at skeletal sites is vertebral (27%), wrist (19%), hip (14%), pelvis (7%) and other (33%). Whilst hip fractures represent only one seventh of the total number of fractures, they accounted for 72% of total costs. More recent studies report that the age-adjusted incidence of hip fractures in the United States has been declining since the mid-1990s<sup>28, 29</sup>. Whilst this is welcome news, the total number of hip fractures occurring continues to present an enormous burden on older Americans and U.S. healthcare systems, primarily Medicare. Although availability of effective osteoporosis medications is coincident with the beginning of the attenuation of hip fracture rates, levels of usage – particularly in high risk patients - cannot fully account for the observed reduction. A similar phenomenon has been observed in Canada<sup>30</sup>, where around 30 000 Canadians break their hip every year<sup>31</sup>. The authors of these studies conclude that there remains huge scope and need to improve fracture prevention efforts.

**Latin America**<sup>25</sup> One of the most startling findings of the recent IOF Audit for Latin America was the dramatic ageing of the populations in the 14 countries evaluated. Currently, the proportion of the populations aged 50 years and over is between 13% and 29%. By 2050, these figures are estimated to increase to between 28% and 49%. The 280% estimated increase in those aged 70 years and over is set to fuel an enormous rise in the prevalence of osteoporosis and incidence of fragility fractures. In Mexico, the number of hip fractures is expected to rise from almost 30 000 in 2005 to more than 155 000 by 2050. Similarly in Argentina, the current incidence of hip fracture at 34 000 cases per year is expected to triple by 2050. In 2006, the direct cost for acute medical care of hip fractures in Mexico approached US\$100 million; by 2025 these costs are projected to increase to between US\$213 million and US\$466 million and by 2050, to between US\$555 million to US\$4.1 billion, according to different projections.

Over the next 20 years, 450 million people will reach their 65th birthday. On account of the ageing of the population, fracture incidence will remain high in the West and presents a major threat to healthcare systems in the East.<sup>32</sup>

**Middle East and Africa**<sup>21</sup> By 2050, the proportion of the population of this region aged over 50 years is expected to increase by 25% to 40%. As a direct result, the projected increase in the incidence of hip fracture is amongst the highest in the world. Turkey provides a useful illustration; 24 000 cases of hip fracture occurred amongst Turks aged over 50 years in 2010, which is expected to increase by 50% by the end of the current decade.

**European Union**<sup>19</sup> This report presents fracture epidemiology for the EU27 countries. The number of new fractures during 2010 in the EU was 3.5 million, comprising approximately 610 000 hip fractures, 520 000 vertebral fractures, 560 000 forearm fractures and 1.8 million other fractures. Two thirds of all incident fractures occurred in women. The cost of osteoporosis, including pharmacological intervention in the EU in 2010 was estimated at €37 billion. Uptake of individual treatments differs between regions in Europe. In general, Southern Europe shows a higher uptake of osteoporosis drugs. There is a marked variation in the availability of bone densitometry, its cost and service provisions in the EU and a majority of countries have insufficient resources to implement practice guidelines.

*million people will celebrate  
nt of this, absolute hip  
in high and costly in the  
reat to financing of health*

**Eastern Europe and Central Asia**<sup>20</sup> Fourteen million Russians currently have osteoporosis. By 2050, 56% of the population will be over 50 years of age, so the disease burden will increase significantly in the coming decades. The number of hip fractures in the Russian Federation is predicted to increase by 23% by 2030, reaching 144 000 cases annually. There is a stark lack of post-fracture hospitalization, with only 13% of hip fracture patients undergoing surgical repair. Consequently, post-hip fracture mortality during the first year after fracture reaches approximately 50% in many Russian cities.


**Asia**<sup>22</sup> In 1995, 5.3% of the population living in Asia was aged 65 years and over; this is projected to increase to 9.3% by 2025, representing a 75% increase for a population of several billion people. In 2009, there were 167 million people aged over 60 years living in China, which will rise to 480 million by 2050<sup>23</sup>. Almost 700 000 hip fractures occur annually in China. Alarming, from 2002 to 2006, hip fracture rates among those over 50 years of age in Beijing increased by 58% in women and 49% in men<sup>24</sup>. Urbanization and changes in lifestyle are proposed as the primary reasons for such a rapid change. In India, 36 million people already have osteoporosis. By 2050 more than 50% of all osteoporotic fractures will occur in Asia. In terms of costs, projections for China illustrate the financial burden that is looming across this region. In 2006, US\$1.6 billion was spent on hip fracture care in China; this is projected to rise to US\$12.5 billion by 2020 and \$265 billion by 2050.

## THE IMPACT OF FRACTURES ON QUALITY OF LIFE

Fragility fractures exact a terrible toll on the quality of life of postmenopausal women across the world. The global burden of osteoporosis can be quantified by disability adjusted life years (DALYs)<sup>33</sup>, which are widely used to measure the impact of a disease on the sufferer's quality of life<sup>34</sup>. In 2000, the total DALYs lost that were attributable to fragility fractures was 5.8 million. This accounts for 0.83% of the global burden of non-communicable disease<sup>18</sup>. Fragility fractures account for the loss of 2 million DALYs in Europe every year. To put this into context, *figure 1* shows the number of DALYs in Europe in 2002 for osteoporosis compared to other major diseases. With the exception of lung cancer, fractures caused by osteoporosis account for more combined deaths and morbidity than any cancer type.

Around the globe, the findings of the IOF regional audits regarding the impact of fragility fractures on quality of life in older women are truly astounding. This is particularly the case for both hip and spine fractures. In Russia, the fact that 87% of hip fracture patients do not undergo surgical repair has appalling consequences for survivors<sup>20</sup>; 33%

**FIGURE 1** Burden of diseases estimated as disability-adjusted life years (DALYs) in 2002 in Europe<sup>18</sup>.



remain bed-ridden, 42% have very limited activities, only 15% can ambulate outside and just 9% return to their previous level of daily activities.

Similarly, in Kazakhstan and Georgia less than 50% and 25% of hip fracture sufferers undergo surgical repair, respectively. The Middle East and Africa Audit<sup>21</sup> reported that mortality after hip fracture may be 2-3 times higher in this region than in Western populations. Amongst

women aged over 80 years in Latin America, 38% had a vertebral fracture<sup>25</sup>. Given that 1 in 5 women with a vertebral fracture will sustain another one within twelve months<sup>35</sup>, implementation of preventive measures should be a priority for health authorities in the region<sup>36</sup>.

Worldwide, osteoporosis is significantly compromising the quality of life of countless postmenopausal women.

WITHOUT PROPER SURGICAL TREATMENT, HIP FRACTURE PATIENTS ARE INVARIABLY LEFT BEDRIDEN AND UNABLE TO WALK. THIS RUSSIAN PATIENT SUFFERED A FRACTURE OF THE FEMUR (HIP) SEVERAL YEARS AGO. SHE DID NOT RECEIVE SURGICAL TREATMENT, OR TREATMENT OF ANY KIND. NOW, EVEN SEVERAL YEARS LATER, SHE IS UNABLE TO WALK. TWICE A DAY, EVERYDAY, HER HUSBAND PUSHES HER IN A WHEELBARROW ALL THE WAY TO TOWN. THIS WAY SHE IS AT LEAST ABLE TO LEAVE THE HOUSE AND MAINTAIN SOME SOCIAL CONTACT.





# POSTMENOPAUSAL WOMEN ARE AT GREATEST RISK

Menopause commonly occurs between age 50 and 53 years in women from Europe and North America, and as early as age 42 years in populations from Latin America and Asia<sup>37</sup>. Postmenopausal women are at high risk of developing osteoporosis and suffering fractures on account of the rapid bone loss which occurs with the onset of menopause<sup>38-40</sup>. As illustrated in *figure 2*, in females, bone mass achieves a peak in the mid-twenties, remains relatively stable thereafter until the beginning of the menopause, whereupon a rapid period of bone loss ensues.

Oestrogen plays a vital role in regulating the bone turnover process throughout life. Every day, our skeletons are undergoing a process of formation and resorption; one group of cells – osteoblasts – lead formation of new bone, whilst another – osteoclasts – resorb old bone. This ongoing process ensures that the skeleton maintains its structural integrity. During most women’s second 25 years of life, formation and resorption are nicely balanced such that bone renewal goes on without adversely affecting

total bone mass. However, as women become oestrogen deficient when menses cease, the equilibrium is lost with bone resorption exceeding bone formation. This imbalance is particularly evident in trabecular bone. In addition to oestrogen deficiency, reduced intestinal calcium absorption, increases in urinary calcium losses, and loss of androgenic, bone protective hormones produced by the ovaries also have an adverse effect on bone health<sup>41-43</sup>. Menopause-induced bone loss is most severe where there is an acute cessation of ovarian function, be it due to surgery, or from the use of aromatase inhibitor therapy in cancer patients<sup>44-47</sup>.

The age-specific incidence of fragility fractures illustrated in *figure 3*, correlates with two factors; postmenopausal bone loss and the increasing propensity to suffer falls as women enter their eighth decade<sup>48</sup>. The pattern and site for classical osteoporotic fractures reflect the earlier and more pronounced loss at skeletal sites most enriched in trabecular bone; that is distal forearm and spine, followed by the hip. This is a result of the larger bone surface and


higher rates of skeletal remodelling in trabecular bone.

The increase in fracture risk as women age is quantified in *table 1*. This demonstrates that the vast majority of fractures occur amongst women aged over 65 years and reinforces the importance of a fragility fracture as a predictor of future fracture risk<sup>50</sup>; **fracture begets fracture**.


**TABLE 1 Five-year risk of first and subsequent fractures in women at any skeletal site<sup>50</sup>.**

Age (years)	First (%)	Subsequent (%)
50-54	1.9	2.8
55-59	2.7	4.2
60-64	4.1	8.9
65-69	6.2	13.5
70-74	9.1	17.6
75-79	13	23.5
80-84	17.1	28.4
85-89	27.9	40.2
90 +	49.1	61.6

**FIGURE 2 Bone mass rapidly decreases with the onset of the menopause<sup>38-40</sup>.**



**FIGURE 3 Age-specific incidence of fragility fractures for women<sup>49</sup>.**



# HOW TO REDUCE OSTEOPOROSIS AND FRACTURE RISK

A growing body of evidence provides guidance for women and their health care providers on how their risk can be reduced. While peak bone mass is highly genetically determined, after 65 years of age genetics play a diminishing role in bone loss<sup>51</sup>. For the half a billion people who will celebrate their 65th birthday during the next two decades<sup>52</sup>, this observation highlights the importance of the following lifestyle measures in maintaining a healthy skeleton. An individual's risk of developing osteoporosis and fragility fractures is determined by a number of factors, some of which can be changed (e.g. exercise, nutrition and smoking) while others cannot (e.g. family history, age at menopause and the presence of diseases such as rheumatoid arthritis). The modifiable risk factors will be considered first.

## EXERCISE

Studies have shown that individuals with a sedentary lifestyle are more likely to have a hip fracture than those who are more active. For example, women who sit for more than nine

hours a day are 43% more likely to have a hip fracture than those who sit for less than six hours a day<sup>53</sup>.

Exercise has been shown in randomised controlled trials to lead to small but statistically significant increases in bone mineral density (BMD) of the order of 1-2%<sup>54, 55</sup>. The recently published Osteoporosis Australia strategy 'Building healthy bones throughout life' reached the following conclusions on the role of exercise for older adults and individuals with low bone mass<sup>56</sup>:

- The positive effect of exercise on bone in older people is dependent upon both the type of exercise and intensity<sup>57-59</sup>.
- Generally, resistance training becomes more beneficial as one ages.
- For fragility fracture sufferers, exercise programmes have been shown to assist recovery of function<sup>60</sup>, prevent recurrent injurious falls<sup>61</sup> and improve quality of life<sup>62</sup>.

The main benefit of exercise appears to be the associated reduction in risk of falling. Bischoff-Ferrari and colleagues compared extended physiotherapy to standard physiotherapy (PT) for elderly patients who had broken their hip<sup>63</sup>. The extended group received 60 minutes PT per day during their acute care compared to half that for the standard group, with the aim of supporting patients to adhere to a 30 minute per day home exercise programme after discharge from hospital. The rate of falls for the extended PT group was 25% lower than the standard group. A similar result was reported previously by Campbell and colleagues for community dwelling women aged 80 years and over in New Zealand<sup>64</sup>. After a year, the rate of falls in the home-based exercise group was half that of the control group.

Exercise programmes need to be highly tailored for the individual dependent upon whether they have osteoporosis, are highly prone to falling or are frail.



IN OLDER ADULTS, WEIGHT-BEARING AND MUSCLE-STRENGTHENING EXERCISES ARE ESSENTIAL FOR THE MAINTENANCE OF BONE AND MUSCLE HEALTH.

# Exercises to build strong bones<sup>65, 66</sup>

## FOR HEALTHY POSTMENOPAUSAL WOMEN WHO DO NOT HAVE OSTEOPOROSIS:

Besides maintaining bone strength, the main goal of exercise therapy in postmenopausal women is to increase muscle mass in order to improve parameters of muscle function such as balance and strength, which are both important risk factors for falls and - independent of bone density – risk factors for fractures.

Exercise should be tailored to the individual's needs and capabilities. Overall, most people should aim to exercise for 30 to 40 minutes three to four times each week, with some weight-bearing and resistance exercises in the programme. The International Osteoporosis Foundation and the U.S. National Osteoporosis Foundation recommendations on exercise are available at <http://www.iofbonehealth.org/exercise-recommendations> and <http://www.nof.org/articles/238>, respectively.

### Examples of weight-bearing exercises include:

- Dancing
- High-impact aerobics
- Hiking
- Jogging/running
- Jumping rope
- Stair climbing
- Tennis

### Examples of muscle-strengthening exercises include:

- Lifting weights
- Using elastic exercise bands
- Using weight machines
- Lifting your own body weight
- Standing and rising on your toes

### Balance, posture and functional exercises also have an important role to play:

- Balance: Exercises which strengthen the legs and test your balance (e.g. Tai Chi) can reduce falls risk<sup>67</sup>
- Posture: Exercises to improve posture and reduce rounded shoulders may reduce fracture risk, particularly at the spine<sup>68</sup>
- Functional exercises: Exercises which help with everyday activities<sup>63</sup>

## SPECIFIC CONSIDERATIONS FOR WOMEN WITH OSTEOPOROSIS<sup>69</sup>:


An exercise programme for people with osteoporosis should specifically target posture, balance, gait, coordination, and hip and trunk stabilization rather than general aerobic fitness. Such a programme was developed by Carter and colleagues in Canada and participants experienced improvements in dynamic balance and strength<sup>70</sup>.

### Several exercises are not suitable for people with osteoporosis:

- Sit-ups and excessive trunk flexion can cause vertebral crush fractures.
- Twisting movements such as a golf swing can also cause fractures<sup>71</sup>.
- Exercises that involve abrupt or explosive loading, or high-impact loading, should be avoided.
- Daily activities such as bending to pick up objects can cause vertebral fracture<sup>72</sup>.







**TABLE 3 Calcium rich foods across a range of food groups**

Food	Serving size (average)	Calcium (mg)
Milk, semi-skimmed	Glass, 200 ml	240
Yoghurt, low-fat, plain	Pot, 150 g	243
Cheese, Edam	Portion, 40 g	318
Curly kale	Serving, 95 g	143
Sesame seeds	1 table spoon	80
Rice pudding, canned	Average portion, 200 g	176
Whitebait, fried	Portion, 80 g	688
Pasta, plain, cooked	Portion, 230 g	85
Figs, ready to eat	4 fruit, 220 g	506
Tofu, soy bean, steamed	100 g	510

## NUTRITION – CALCIUM, VITAMIN D AND OTHER NUTRIENTS

### Calcium

Practically all of our calcium resides in our bones – 99% of the 1 kg of calcium found in the average adult body – so calcium is a major building block of our skeleton. The calcium in our bones also acts as a reservoir for maintaining calcium levels in the blood, which is essential for nerve and muscle function. Throughout the course of our lives, the amount of calcium we need changes. As the skeleton rapidly grows during the teenage years, calcium needs are high. As the body's ability to absorb calcium declines with advancing age<sup>73</sup>, the requirements of older people also increase. *Table 2* provides information on recommended calcium intake for several countries and from global organizations.

During the last few years there has been significant debate in the scientific literature on how best individuals can

ensure they have adequate intake of calcium to support a healthy skeleton. A clear message from this debate is that diet should be the primary source of calcium. *Table 3* highlights a list of 10 calcium rich foods across a range of food groups.

Studies from Australia<sup>80</sup> and the United States<sup>78</sup> have reported a significant gap between the recommended and actual calcium intake in the population. For older women in the United States this gap is of the order 450 mg per day<sup>78</sup>. On account of this, calcium supplementation has played a role to ensure older individuals are calcium replete. Whilst calcium intake at the recommended levels is considered safe, considerable attention in the media has focused on the safety of high dose calcium supplements in light of recent analyses. An increase in the incidence of kidney stones in women taking high dose supplements (but not men) has been reported<sup>81, 82</sup>. The opposite is evident for women<sup>81</sup> (and men<sup>83</sup>) achieving high calcium intake from their diet.

The current debate on the safety of high dose calcium supplements is focused upon the risk-benefit ratio in terms of the risk of cardiovascular disease. In 2008, Bolland and colleagues reported that treatment of healthy postmenopausal women with 1000 mg of supplemental calcium doubled the risk of myocardial infarction (heart attack) in comparison to women treated with placebo<sup>84</sup>. Other studies have reported inconsistent results, however, none have found an association between increased risk of cardiovascular disease and dietary calcium intake<sup>85-88</sup>. The recent Osteoporosis Australia strategy extensively evaluated this issue and concluded<sup>56</sup>:

*Calcium or calcium-vitamin D supplements may be beneficial for general health as well as reducing fracture risk in people who may not be getting enough calcium through their diet<sup>89</sup>. Nevertheless, dietary calcium is the preferred source of calcium, and calcium supplements should be limited to 500-600mg per day.*

**TABLE 2 Recommended daily calcium intake for several countries**

Country	Age range	Calcium intake (mg)	Organization
Australia	51-70 years	1300 (RDI)	National Health and Medical Research Council <sup>74</sup>
	> 70 years	1300 (RDI)	
Canada	≥ 50 years	1200	Osteoporosis Canada <sup>75</sup>
Korea	≥ 50 years	700	Korean Nutrition Society <sup>76</sup>
UK	≥ 50 years	700	Department of Health <sup>77</sup>
USA	51-70 years	1200 (DRI)	Institute of Medicine <sup>78</sup>
	≥ 71 years	1200 (DRI)	
WHO/FAO	postmenopausal women	1300	WHO/FAO 2002 <sup>79</sup>

**RDI** Recommended Dietary Intake • **DRI** Dietary Reference Intake

## Vitamin D

Vitamin D is primarily synthesised in the skin after sun exposure and plays a crucial role in bone and muscle development, function and preservation<sup>90</sup>. Vitamin D can contribute to reducing fracture risk through the following mechanisms:

- ### Calcium homeostasis and Bone Mineral Density

1,25-dihydroxyvitamin D (the active form of vitamin D) and parathyroid hormone (PTH) are the two most important hormones for regulation of calcium levels in the body (see figure 4). Serum levels of 25-hydroxyvitamin D are inversely related to serum levels of PTH and positively associated with BMD<sup>91-93</sup>.

- ### Muscle performance

Data from the Third National Health and Nutrition Survey

(NHANES III) in the United States reported a correlation between lower extremity muscle performance and levels of 25-hydroxyvitamin D<sup>94</sup>.

- ### Balance

In the clinical trial setting, balance has been measured in terms of the degree of sway experienced by subjects standing on a force platform. Body sway was reduced by up to 28% amongst older study participants who received vitamin D in addition to calcium compared to those receiving calcium alone<sup>95,96</sup>.


- ### Falls risk

Vitamin D administered at doses in the range 700 – 1,000 IU per day has been associated in meta-analyses with a reduction in falls incidence of around one fifth<sup>97,98</sup>.

- A considerable number of randomised controlled trials have evaluated the effect of vitamin D supplementation on fracture rates in older women and men. It is generally agreed that vitamin D lowers fracture risk<sup>78,99</sup>, but there is currently no consensus on the serum 25-hydroxyvitamin D level needed for optimal benefit. For the general population, the level of 50 nmol/L is considered optimal<sup>78</sup>, whereas many clinical guidelines recommend a level of 75 nmol/L<sup>90,99</sup>.

Low levels of vitamin D in the population are a cause of concern around the world. In 2009, an IOF Working Group published a review of global vitamin D status and determinants of hypovitaminosis D<sup>100</sup>. Based on a definition of vitamin D insufficiency as a level of 25-hydroxyvitamin D of <75 nmol/L

**FIGURE 4 The role of vitamin D in bone health**



(30 ng/ml), insufficiency was highly prevalent in all six regions studied (Asia, Europe, Middle East and Africa, Latin America, North America, and Oceania). Further, vitamin D deficiency – defined as <25 nmol/L (10 ng/ml) – was most common in the Middle East and South Asia.

In 2010, IOF published a position statement on vitamin D recommendations for older adults<sup>90</sup>. The estimated average vitamin D requirement for older adults to achieve a serum 25-hydroxyvitamin D level of 75 nmol/L (30 ng/ml) is 20 to 25 µg per day (800 to 1,000 IU per day). However, considerably higher doses would be needed to ensure that almost all older adults achieved the target level. In high-risk individuals, measurement of serum 25-hydroxyvitamin D is recommended. The required dose of vitamin D could be estimated based upon the notion that each 2.5 µg (100 IU) per day added will increase serum 25-hydroxyvitamin D by about 2.5 nmol/L (1 ng/ml)<sup>101</sup>. Re-testing after three months of supplementation is recommended for high-risk individuals to confirm that target levels have been achieved.

## Protein

Body composition changes after middle age, including increases in fat mass and decreases in lean mass (i.e. muscle). One modifiable component of this sarcopenic process is dietary protein intake. The Health ABC Study in the United States evaluated body composition, weight-related health conditions and incident functional limitations in older adults<sup>102</sup>. Those participants in the highest quintile for protein intake lost 40% less lean mass and non-bone appendicular mass than those in the lowest quintile of protein intake. Further, the Framingham Osteoporosis Study provided evidence of the effect of dietary protein on bone loss in older people<sup>103</sup>. Both lower protein intake and lower animal protein intake were associated with loss of BMD at the hip and spine. Notably, the effect was comparable to that of the well documented negative effects of smoking or lower weight (4.5 kg, 10 lb) on BMD. Another study highlighted the need for individuals to achieve an adequate calcium intake

in order for the beneficial effect of protein on BMD to be realised<sup>104</sup>.

## Acid-base balance of the diet

The impact of acid-base balance on bone is a comparatively new area of research. Investigation of the effect of aging on blood acid-base composition suggests that reduced renal function in older people diminishes the kidney's ability to excrete hydrogen ions in response to changes in blood pH<sup>105</sup>. Accordingly, healthy adults manifest a low-grade diet-dependent metabolic

Lower protein intake is associated with loss of bone mineral density at the hip and spine. Diets rich in fruits and vegetables have been shown to be associated with higher bone mineral density.

acidosis which increases with age. Diet can contribute to acidosis when alkali-producing fruits and vegetables are consumed in insufficient amounts to balance the intake of acid-producing foods such as cereal grains and protein. The organic acids in fruits and vegetables are metabolized to alkaline bicarbonate; cereal grains

contribute phytic and other acids and protein adds acid in proportion to its content of sulphur-containing amino acids (which are metabolized to sulphuric acid).

An acidic environment has negative effects on preservation of bone in that it can impair bone forming cells<sup>106-108</sup>, activate bone resorption<sup>109, 110</sup>, as well as exert a direct chemical effect on bone<sup>111</sup>.

To accommodate the need of older women for protein, the dietary acid load can be lowered by decreasing intake of cereal grains. Increasing intake of fruits and vegetables is another good option. Diets rich in fruit and vegetables have been shown to be associated with higher BMD and/or lower propensity for bone loss<sup>112-116</sup>.

## LIFESTYLE FACTORS WITH NEGATIVE IMPACT ON BONE

### Smoking

Current smokers and those who have smoked in the past are at increased risk of any fracture, compared to non-smokers<sup>117</sup>. Smoking is associated with several risk factors for osteoporosis including early menopause<sup>118</sup> and thinness<sup>119</sup>. Another mechanism through which smoking may impact on bone health is acceleration of oestrogen metabolism<sup>120</sup>.

### Alcohol

Alcohol taken in moderation – up to two glasses (2 x 120 ml) of wine per day - does not negatively impact on bone health. A Finnish study reported that mild to moderate alcohol intake was actually associated with greater bone mass amongst postmenopausal women<sup>121</sup>. A recent study suggests that the inhibitory effect of alcohol on bone turnover attenuates excessive bone turnover associated with menopause<sup>122</sup>. However, long-term heavy alcohol use has been shown to increase fracture risk in women and men<sup>123</sup>. The mechanisms by which alcohol may adversely affect fracture risk include:

- Alcohol has direct effects on osteoblasts (bone-forming cells)<sup>124</sup>.
- Alcohol increases the endogenous



secretion of calcitonin, a hormone which suppresses resorption of bone by inhibiting the activity of osteoclasts<sup>125</sup>. Calcitonin also inhibits reabsorption of calcium and phosphorus in the kidney, leading to increased rates of their loss in urine.

- Heavy drinkers may have poor nutrition with respect to calcium, vitamin D, or protein<sup>126</sup>.
- Alcohol increases the risk of falls<sup>127</sup> or interferes with the protective response to injury<sup>128-130</sup>.

### Maintaining a healthy weight

Leanness – defined as a body mass index (BMI)  $<20 \text{ kg/m}^2$  - regardless of age, sex and weight loss, is associated with greater bone loss and increased risk of fracture. People with a BMI of  $20 \text{ kg/m}^2$  have a two-fold increased risk of fracture compared to people with a BMI of  $25 \text{ kg/m}^2$ <sup>131</sup>.

Whilst anorexia is primarily of concern in younger women, the associated malnutrition, thinness and accompanying loss of oestrogen is devastating to bone health and dental health<sup>132</sup>.

The elderly are particularly vulnerable to malnutrition and it is important that seniors, or their caregivers, ensure sufficient caloric intake. As they age, individuals may be less capable of making the effort to prepare balanced meals, have less appetite, or suffer from chronic diseases and use medications that may impair appetite. A taskforce in the UK found that 14% of older people are at risk of malnutrition<sup>133</sup>. An evaluation based on BMI showed that in the UK 5% of older people living at home are underweight (BMI  $<20 \text{ kg/m}^2$ ), a figure that rises to 9% for those with chronic diseases.

AS WELL AS SUFFICIENT CALCIUM, VITAMIN D AND PROTEIN, A 'BONE HEALTHY DIET' SHOULD ALSO BE RICH IN FRUITS AND VEGETABLES.



# INDIVIDUAL RISK FACTORS

To enable women and their health care professionals to identify which individuals are at high risk of suffering osteoporotic fractures, awareness of the following non-modifiable risk factors is paramount.

## PREVIOUS FRAGILITY FRACTURES

Osteoporosis is a chronic disease which is manifested in the form of fragility fractures – defined as fractures which occur as a result of low trauma, and usually result from a fall from standing height. Fragility fractures are very common: 1 in 3 postmenopausal women will suffer at least one during their remaining lifetime<sup>15, 16</sup>. Several studies have evaluated future fracture risk associated with suffering fractures at various skeletal sites. Two meta-analyses reported that a prior fracture at any site is associated with a doubling of future fracture risk<sup>134, 135</sup>. From the obverse perspective, about half of patients presenting with hip fractures have previously broken another bone before breaking their hip<sup>136-139</sup>.

The 16% of postmenopausal women whom have already suffered a fragility fracture are the most readily identifiable group of individuals at high risk of suffering second and subsequent fractures<sup>140, 141</sup>. Despite a broad range of effective medications for osteoporosis being available in many countries, a ubiquitous care gap is evident for those that have suffered fragility fractures<sup>142</sup>. In response to this, IOF devoted the 2012 World Osteoporosis Day Report<sup>143</sup> to the Capture the Fracture Campaign<sup>144</sup>, which aims to close the post-fracture care gap worldwide:

- If you are a postmenopausal woman who has suffered a fragility fracture, seek advice from your doctor on how to reduce your future fracture risk.
- If you are a health care professional, you should ensure that any patient aged 50 years

or over who has suffered a fracture is assessed and treatment is considered. Visit [www.capturethefracture.org](http://www.capturethefracture.org) to read about effective systems for secondary fracture prevention and consider implementing a Fracture Liaison Service in your locality.

- If you are a health care policy maker, visit [www.capturethefracture.org](http://www.capturethefracture.org) to read about approaches taken in other countries to prioritise secondary fracture prevention initiatives in health care policy.

Postmenopausal women who have suffered a fragility fracture should seek advice from their doctors on how to reduce future fracture risk.

## FAMILY HISTORY OF OSTEOPOROSIS AND FRACTURES

Genetics have considerable influence upon the peak bone mass attained by an individual<sup>145-147</sup> and, in the case

of postmenopausal women, the rate of bone loss in the early years after menopause<sup>51</sup>. Heritability is evident as long as bone metabolism is primarily determined by physiological factors, such as hormonal levels and the activity of bone forming osteoblast cells. With advancing age, the impact of comorbid conditions, immobility, nutrition and absorption issues, and neurodegenerative disorders becomes dominant.

A parental history of fracture is associated with an increased risk of fracture that is independent of bone mineral density<sup>148</sup>. For women, the risk ratio is 1.17, 1.18 and 1.38 for any fracture, osteoporotic fracture and hip fracture, respectively.

## MEDICATIONS

Glucocorticoid (GC) treatment is the most common cause of drug-induced osteoporosis. Glucocorticoid-induced osteoporosis (GIO) is primarily a disease of reduced bone formation affecting osteoblast cell function. However, GCs also prolong the life span of bone resorbing osteoclast cells and impair the function of osteocyte cells embedded in bone, which have been described as the 'orchestrator of bone remodelling' on account of the osteocyte's regulation of both osteoclast and osteoblast cell activity and additional function as an endocrine cell<sup>149</sup>.

The effect of GCs on bone is rapid, with a significant proportion of bone loss occurring in the first 6 months of treatment. GCs effects are dose related so it is important that patients take the lowest effective dose for the shortest possible length of time. The prevalence of asymptomatic vertebral fractures among postmenopausal women receiving chronic GC therapy in an Italian study ranged from 30% for those aged under 60 years to 50% among those aged over 70 years<sup>150</sup>. These prevalence rates are considerably higher than those reported in the general





postmenopausal population, which ranged from 12-20% in the European Vertebral Osteoporosis Study<sup>151</sup>.

Both anabolic (bone forming)<sup>152</sup> and anti-resorptive<sup>153, 154</sup> pharmacotherapies have been demonstrated to prevent GIO bone loss and fragility fractures. Adequate calcium and vitamin D are also essential adjunctive measures in the effective treatment of GIO. However, despite publication of professional guidelines on the need for bone prophylaxis in GC treated individuals<sup>155, 156</sup>, a significant care gap has been reported<sup>157, 158</sup>. Awareness of the risk that GC treatment presents to bone health must be increased amongst both patients and health care professionals.

### **DISEASES OF MALABSORPTION**

Low bone mass is highly prevalent amongst sufferers of Crohn's disease<sup>159, 160</sup> and celiac disease<sup>161</sup>. Many factors contribute to this association: in Crohn's disease these include intestinal resection and the resulting malabsorption of vitamin D and other nutrients, weight loss, chronic inflammation with increased levels of circulating cytokines, and frequent use of glucocorticoids. The major causes of osteoporosis amongst sufferers of malabsorption are malnutrition of calcium, vitamin D, protein and other nutrients, and the accompanying weight loss.

Professional guidelines on osteoporosis prevention and management in

inflammatory bowel disease and celiac disease have been published<sup>162</sup>.

### **RHEUMATOID ARTHRITIS**

Sufferers of rheumatoid arthritis (RA) have lower BMD and are at increased risk of fracture<sup>163, 164</sup>. RA is the only secondary cause of osteoporosis in the FRAX<sup>®</sup> algorithm that is considered a predictor of fracture independent of bone density<sup>165</sup>. The degree of bone loss observed in RA is correlated with the severity of disease activity<sup>166</sup>. Proinflammatory cytokines released into the circulation from the inflamed synovium are thought to cause the bone loss.

### **EARLY MENOPAUSE**

Premature menopause (before age 40 years) and early menopause (between ages 40 and 45 years) are associated with osteoporosis and a range of other health concerns<sup>167</sup>. The earlier the menopause occurs, the lower the bone density will be later in life<sup>168</sup>. Women who undergo oophorectomy (surgical removal of the ovaries) before age 45 years are at increased risk of developing osteoporosis. The loss of oestrogen triggers an increase in bone resorption and rapid bone loss (about 2-3% per year) which continues for about 5 to 8 years after menses cease. Thereafter, bone loss will slow to around 1% per year. Women who experience premature or early menopause should consider having a bone density scan conducted within 10 years of their menopause<sup>168</sup>.

## **Medical treatments affecting bone health**

Some medications may have side effects that directly weaken bone or increase the risk of fracture due to fall or trauma. Patients taking any of the following medications should consult with their doctor about increased risk to bone health:

- Glucocorticosteroids
- Certain immunosuppressants (calmodulin/calcineurin phosphatase inhibitors)
- Excess thyroid hormone treatment (L-Thyroxine)
- Certain steroid hormones (medroxyprogesterone acetate, luteinising hormone releasing hormone agonists)
- Aromatase inhibitors
- Certain antipsychotics
- Certain anticonvulsants
- Certain antiepileptic drugs
- Lithium
- Antacids
- Proton pump inhibitors



# TAKE ACTION FOR A BREAK-FREE FUTURE

Menopause is a critical point in a woman's lifetime to discuss bone health with her primary care provider. Whilst the majority of fractures caused by osteoporosis occur in postmenopausal women<sup>170-172</sup> a significant awareness gap exists in this group. An IOF

In view of these challenges, the previously described profound metabolic changes and anticipated acceleration in age-related bone loss with the menopause transition, it is essential that preventive measures be taken at menopause to optimize

Good nutrition and an active lifestyle are essential to optimizing health in general, and musculoskeletal health in particular. They are the key foundations for osteoporosis prevention strategies in both genders, and across the lifecycle, but become

Worldwide, at 50 years of age, 1 in 3 women will suffer a fracture in their remaining lifetime, and in women over 45 years of age, osteoporosis accounts for more days spent in hospital than many other diseases, including diabetes, myocardial infarction (heart attack) and breast cancer<sup>169</sup>.

survey, conducted in 11 countries, showed denial of personal risk by postmenopausal women, lack of dialogue about osteoporosis with their doctor, and restricted access to diagnosis and treatment before the first fracture, resulting in under-diagnosis and under-treatment of the disease<sup>173</sup>.

bone health. This includes specific recommendations for calcium and vitamin D supplementation, other supplements, exercise, need for bone density measurements, fracture risk assessment, and potential need for pharmacologic intervention and follow-up.

particularly relevant with increased requirements for certain nutrients, after the menopause. The 2011 World Osteoporosis Day campaign message 'Embrace a bone healthy lifestyle' underscored the benefits derived from healthy nutrition, adequate vitamin D supplementation, and engaging in

## Questions patients should ask their doctor at a check up

- What are lifestyle changes I can implement at menopause to optimize bone health?
- What are recommendations for calcium, vitamin D and exercise?
- My mother had a hip fracture/or had a hump. What is my risk for fractures?
- Should I have a bone density test and how often should it be repeated?



physical activity to ensure stronger muscles and bones<sup>174</sup>.

## TOOLS TO ASSESS FRACTURE RISK

### The WHO Fracture Risk Calculator - FRAX<sup>®</sup>

An individual's risk of developing chronic diseases, be it cardiovascular or cerebrovascular diseases or cancer is dependent on disease-specific risk factors, including lifestyle and clinical predictors, as well as family history. Osteoporosis and fragility fractures are no exception. Osteoporosis risk assessment is based on nutritional, other lifestyle variables, illness and medications, and family history, predictors that have been carefully described in the literature and reviewed in this report. In the last decade, tools to assess fracture risk have become available.

### FRAX<sup>®</sup> – how it helps assess 10-year risk, and how to interpret the results<sup>175</sup>

FRAX<sup>®</sup> is a computer-based algorithm introduced in 2008 ([www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)) which calculates the 10-year probability of a major fracture (hip, clinical spine, humerus or wrist fracture) and, individually, the 10-year probability of hip fracture<sup>176</sup>. This user friendly tool is designed to allow health care providers assess fracture risk at the individual level, target

pharmacologic therapies to those at high risk, and thus prevent future fractures.

Fracture probability is computed taking both the risk of fracture and the risk of death into account. The algorithm had been constructed using information derived from the primary data of 9 population-based cohorts from around the world, including centres from North America, Europe, Asia and Australia, and was then validated in 11 independent cohorts with a similar geographic distribution with an excess of 1 million individuals<sup>177</sup>.

Fracture risk is calculated from age, body mass index and dichotomized risk factors comprising prior fragility fracture, parental history of hip fracture, current tobacco smoking, alcohol consumption, ever use of long-term oral glucocorticoids, rheumatoid arthritis, and other causes of secondary osteoporosis. Secondary causes of osteoporosis are type I (insulin dependent) diabetes, osteogenesis imperfecta in adults, untreated long-standing hyperthyroidism, hypogonadism or premature menopause (<45 years), chronic malnutrition, or malabsorption and chronic liver disease<sup>177</sup>. Risk factors included in FRAX<sup>®</sup> were chosen to include only well-recognized, validated, and independent contributors to fracture risk while limiting their number and complexity<sup>178</sup>. Femoral neck BMD

can be optionally input to enhance fracture risk prediction. The use of clinical risk factors in conjunction with BMD and age improves sensitivity of fracture prediction without adverse effects on specificity.

Since its launch in 2008, FRAX<sup>®</sup> has created a paradigm shift in care pathway models, and has become the cornerstone for the development of organization-based as well as national, osteoporosis guidelines<sup>177,179-181</sup>. In addition to its ease of use and wide availability on-line and through smart phones, FRAX<sup>®</sup> has added unique beneficial features compared to other risk calculators, including the fact that it takes into account country population-specific longevity rates as well as hip fracture incidence rates, thus providing risk estimates of direct relevance to the individual and allowing the development of country specific guidelines based on specific intervention thresholds<sup>180, 182-186</sup>.

Today, FRAX<sup>®</sup> calculators are available for 51 countries which can be accessed online at [www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX). Other models for countries without FRAX<sup>®</sup> will be developed, when sufficient data become available. In the absence of a FRAX<sup>®</sup> model for a particular country, a surrogate country should be chosen, preferably based on the likelihood that it is representative of the index country, and that best approximates the fracture risk of the index country.

As with all risk assessment tools, FRAX<sup>®</sup> is a tool which is complementary to clinical judgement when a physician decides to make a treatment decision. Clinicians should be aware of several limitations. The FRAX<sup>®</sup> assessment takes no account of dose responses for several risk factors such as smoking, steroid dose, presence of multiple fractures, and does not take some important risk factors into consideration, such as falls risk, markers of bone remodelling, and bone mineral measurements at other sites. These limitations acknowledged, FRAX<sup>®</sup> provides physicians and patients with an excellent basis on which to assess and discuss the individual's risk of future fracture.

FIGURE 5 The FRAX<sup>®</sup> on-line calculator and output<sup>177</sup>.



## OTHER FRACTURE RISK CALCULATORS

Other fracture risk calculators exist, such as QFracture<sup>®187</sup>, the Garvan fracture risk calculator<sup>188</sup>, but differ from FRAX<sup>®</sup> in their calculation of incidence rates rather than absolute probabilities. In FRAX<sup>®</sup>, fracture probability is computed taking both the risk of fracture and the risk of death into account. This is important because some of the risk factors affect the risk of death as well as the fracture risk. Examples include increasing age, sex, low body mass index (BMI), low BMD, use of glucocorticoids and smoking. FRAX<sup>®</sup> therefore combines clinical risk factors, BMD and country-specific mortality and fracture data, to calculate 10-year fracture probabilities in individual patients and provides a platform to assist clinicians and public health agencies in making rational treatment decisions based on treatment thresholds. FRAX<sup>®</sup> does not, however, define intervention thresholds, which depend on country-specific considerations, and vary from one country to another.

## INTERVENTION THRESHOLDS BY NATIONAL ORGANIZATIONS

It is universally agreed that patients who suffer fragility fractures should undergo assessment for future fracture risk<sup>26,140,143,144,180,182,189,207</sup>. Most clinical guidelines and reimbursement criteria for specific osteoporosis medication support treatment of the majority of these fracture patients. However, targeting treatment is particularly important for other patients, including younger postmenopausal women, using FRAX<sup>®</sup>.

Country-specific FRAX<sup>®</sup>-based intervention thresholds, are usually developed targeting patients who do not suffer from severe osteoporosis or fragility fractures, and are based on any one of three paradigms:

- A fixed threshold that is independent of age, such as defined by the National Osteoporosis Foundation in the United States<sup>182</sup> and Osteoporosis Canada<sup>180</sup>.
- An age-dependent increasing threshold, such as defined by National Osteoporosis Guideline

Group (NOGG) in the United Kingdom<sup>184</sup> and by the Swiss Association against Osteoporosis in Switzerland<sup>208</sup>. The French also use a FRAX based age-dependent threshold, but only in subjects with a T-score > -3.0 at the spine, hip, or forearm<sup>209</sup>.

- A hybrid model, such as developed for Lebanon, which uses a fixed threshold up to age 70 years, and an age dependent increasing threshold, modelled on the NOGG model, after age 70<sup>186</sup>.

Illustrations of how fracture risk assessment features in several national guidelines follows.

### United States: National Osteoporosis Foundation 2013 Clinician's Guide

The National Osteoporosis Foundation's treatment recommendations include<sup>182</sup>:

- Consider initiating pharmacologic treatment in those with hip or vertebral (clinical or asymptomatic) fractures.
- Consider initiating therapy in those with T-scores < -2.5 at the femoral neck, total hip or lumbar spine by dual-energy x-ray absorptiometry (DXA), after appropriate evaluation.
- Consider initiating treatment in postmenopausal women and men age 50 years or older with low bone mass (T-score between -1.0 and -2.5, osteopenia) at the femoral neck, total hip or lumbar spine by DXA and a 10-year hip fracture probability > 3% or a 10-year major osteoporosis-related fracture probability > 20% based on the U.S.-adapted WHO absolute fracture risk model (FRAX<sup>®</sup>; [www.NOF.org](http://www.NOF.org) and [www.shef.ac.uk/FRAX](http://www.shef.ac.uk/FRAX)).

### Canada: 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis

The 2010 guidelines from the Scientific Advisory Council of Osteoporosis Canada highlight that management of osteoporosis should be guided by an assessment of the patient's absolute

fracture risk based on a validated fracture prediction tool<sup>180</sup>. Specific recommendations include:

- Pharmacologic therapy should be offered to patients at high absolute risk (> 20% probability of a major osteoporotic fracture over 10 years).
- Individuals over age 50 years who have had a fragility fracture of the hip or vertebra and those who have had more than one fragility fracture are at high risk for future fractures, and such individuals should be offered pharmacologic therapy.
- For those at moderate risk of fracture, patient preference and additional risk factors should be used to guide pharmacologic therapy.

### United Kingdom: National Osteoporosis Guidelines Group (NOGG)

The NOGG guideline treatment recommendations are summarised as follows<sup>184</sup>:

- Postmenopausal women with a prior fragility fracture should be considered for treatment without the need for further risk assessment, although BMD measurement may sometimes be appropriate, particularly in younger postmenopausal women.
- Assessment by the FRAX<sup>®</sup> tool should be undertaken in all postmenopausal women without fracture but with a WHO risk factor or a BMI < 19kg/m<sup>2</sup>.

Following the assessment of fracture risk obtained by entering risk factors only into FRAX<sup>®</sup>, the patient may be classified to be at low, intermediate or high risk.

- **LOW RISK** Reassure and reassess in 5 years or less depending on the clinical context.
- **INTERMEDIATE RISK** Measure BMD and recalculate the fracture risk to determine whether an individual's risk lies above or below the intervention threshold.



- **HIGH RISK** Can be considered for treatment without the need for BMD, although BMD measurement may sometimes be appropriate, particularly in younger postmenopausal women.


The intervention threshold is age specific, and is set at a risk equivalent to that of a women with an equivalent age and a history of prior fracture, as calculated by FRAX®, and therefore rises with age. As fracture risk rises markedly with increasing age, the proportion of women in the UK potentially eligible for treatment rises from 20-40% with age.

### INDICATIONS FOR BONE MINERAL DENSITY TEST

Numerous national<sup>180,182,184</sup>, regional and local guidelines are available which describe indications for BMD testing, many with an overlap in some but not all indications, and are captured by the recommendations provided by the International Society for Clinical Densitometry (see <http://www.iscd.org/>). The key indications for BMD testing amongst postmenopausal women are:

- Previous fragility fracture
- Family history of osteoporosis and/or fragility fracture
- Use of certain medications, particularly:
  - Glucocorticoids
  - Aromatase inhibitors
- Diseases of malabsorption, primarily:
  - Crohn’s disease
  - Celiac disease
- Rheumatoid Arthritis
- Early menopause, either:
  - Premature (under age 40 years)
  - Early (40 to 45 years)

**FIGURE 6 The UK NOGG guideline algorithm<sup>210</sup>.**



BONE MINERAL DENSITY TESTING IS A SIMPLE AND NONINVASIVE PROCEDURE.



## PHARMACOLOGIC MANAGEMENT OF OSTEOPOROSIS

The cornerstone of preventive strategies for all patients regardless of risk include lifestyle interventions: weight-bearing, balance and strengthening exercises, smoking cessation, and optimization of total calcium and vitamin D intake. For patients at risk of falls, advice on fall-prevention should be provided. Drug therapies are needed in addition for patients at high risk for fractures, as defined by the NOF<sup>182</sup>, NOGG<sup>184</sup> and Osteoporosis Canada guidelines<sup>180</sup>, or those of another appropriate national organization. Although the major pivotal trials for established drug therapies randomized patients with low bone density and/or fragility fractures, none of them randomized subjects based on actual fracture risk assessment. However, post-hoc analyses revealed that a high FRAX<sup>®</sup>, in some trials, was able to identify subjects who would benefit most from pharmacologic intervention<sup>211-214</sup>.

Several recent reviews detailed the anti-fracture efficacy of approved treatments for postmenopausal women with osteoporosis when given with calcium and vitamin D (see table 4)<sup>215-220</sup>.

Details of the therapies licensed for the treatment of osteoporosis

throughout the world follow (in alphabetical order):

**Bisphosphonates** Represent the cornerstone therapeutic modality for osteoporosis. These analogues of naturally occurring pyrophosphate can be administered orally in weekly or monthly regimens (alendronate, risedronate, and ibandronate) or intravenously every three months (ibandronate) or yearly (zoledronate)<sup>179,218,221,222</sup>. The anti-resorptive action of bisphosphonates persists following discontinuation of therapy. Potential concerns regarding long term use of bisphosphonates have stemmed from associations with rare but serious adverse events, including atypical sub-trochanteric fractures and osteonecrosis of the jaw. This has led to re-consideration of optimal treatment duration and the importance of drug holidays<sup>218, 221</sup>. These agents are widely available, affordable, and in view of their established efficacy and limited toxicity profile, are considered as the first line therapeutic option for many patients<sup>179, 215, 216, 219, 222</sup>.

**Denosumab** A very potent anti-resorptive compound, a humanized monoclonal antibody against RANKL, a member of the tumor necrosis factor superfamily of compounds, agents that are essential for bone resorption. Denosumab is administered subcutaneously twice a year, and

in contrast to bisphosphonates its anti-resorptive effect subsides upon its discontinuation, which may be an advantage or disadvantage depending on whether viewed from the point of view of reducing side effects, or persisting efficacy. Both osteonecrosis of the jaw and atypical subtrochanteric fracture have now been described in denosumab treated patients, but similar to bisphosphonates, the occurrence of the former is more common when used in patients suffering from cancer rather than osteoporosis. The efficacy of denosumab is significant for protection against vertebral, non-vertebral and hip fractures, and it compares very favorably against other anti-resorptive medications. Due to its relatively recent release, the long term safety of denosumab based on post-marketing experience remains to be established.

### Hormone Replacement Therapy

In the Women's Health Initiative trials hormone replacement therapy (HRT) was shown to reduce hip and non-vertebral fractures in older postmenopausal women, mean age 65 years<sup>223, 224</sup>. This was, however, at the expense of an increased risk for several adverse outcomes. These include cardiovascular disease, cerebrovascular disorders, and breast cancer, in the trial using oestrogen (Premarin<sup>®</sup>) combined with progesterone (medroxy-progesterone acetate), and

**TABLE 4 Anti-fracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with Calcium and Vitamin D as derived from controlled trials<sup>215</sup>.**

	Effect on vertebral fracture risk		Effect on non-vertebral fracture risk	
	osteoporosis	established osteoporosis <sup>a</sup>	osteoporosis	established osteoporosis <sup>a</sup>
Alendronate	+	+	n/a	+ (including hip)
Risedronate	+	+	n/a	+ (including hip)
Ibandronate	n/a	+	n/a	+ <sup>b</sup>
Zoledronic acid	+	+	n/a	+ <sup>c</sup>
HRT	+	+	+	+ (including hip)
Raloxifene	+	+	n/a	n/a
Teriparatide and PTH	n/a	+	n/a	+ <sup>d</sup>
Strontium ranelate	+	+	+ (including hip <sup>b</sup> )	+ (including hip <sup>b</sup> )
Denosumab	+	+ <sup>c</sup>	+ (including hip)	+ <sup>c</sup>

**n/a** no evidence available

**+** effective drug

<sup>a</sup> women with a prior vertebral fracture

<sup>b</sup> in subsets of patients only (post hoc analysis)

<sup>c</sup> mixed group of patients with or without prevalent vertebral fractures

<sup>d</sup> shown for teriparatide only

mostly cerebrovascular diseases in the trial using oestrogen (Premarin®) alone, in women who underwent a hysterectomy<sup>223, 224</sup>. It is therefore not an optimal treatment choice in older postmenopausal women. However, short term use of HRT remains an option in a younger women with menopausal symptoms and no contra-indications to its use. Two trials, ELITE (Link) and KRONOS<sup>225,226</sup>, will provide some insight into the safety and efficacy of HRT in younger postmenopausal women.

**Raloxifene** A tissue selective oestrogen receptor modulator (SERM) that is used for the prevention and treatment of osteoporosis. Raloxifene reduces the risk of vertebral fractures, but not hip fractures, and has the added advantage of reducing the risk of breast cancer, without any adverse effect on the endometrium. It does not seem to affect the risk of cardiovascular disorders, but, similar to HRT, increases the risk of venous thromboembolism. It provides a good therapeutic option in late postmenopausal women at high risk for vertebral but not hip fractures and with concerns regarding breast cancer risk.

**Strontium ranelate** An orally active drug, strontium ranelate is

most effective in reducing the risk of vertebral fractures and to a lesser extent non-vertebral fractures. It is approved in Europe by the European Medicines Agency (EMA) for the treatment of osteoporosis, but is not available in the USA. Post-marketing surveillance studies revealed the possibility of severe skin reactions, therefore it should be discontinued permanently if a skin reaction develops. Recent guidance from the EMA, as a result of trial and surveillance data, has advised that strontium ranelate should not be used in those with high cardiovascular risk or where there is a high risk of thromboembolic disease. Other strontium compounds, often marketed over the internet, have not been demonstrated to be effective and should not be used to treat osteoporosis.

**Teriparatide** Subcutaneous administration of parathyroid hormone results in an anabolic (bone forming) action at multiple skeletal sites. While the sequential use with a subsequent anti-resorptive agent is essential to prevent the significant bone loss noted after its discontinuation, concomitant administration with bisphosphonates does not provide any added benefit. The occurrence of osteosarcoma in

rats, when used at doses several fold higher than those administered in humans, has led regulatory agencies to limit its use to two years, but post-marketing surveillance did not reveal any concerns in humans. Teriparatide has been shown to reduce the risk of vertebral and non-vertebral fractures, but not of hip fractures, and its use is indicated in subjects with severe osteoporosis, and/or multiple vertebral fractures<sup>215, 217</sup>.

The overall safety profile for the above therapies is favorable. Cost implications differ, generic bisphosphonates being the most affordable, followed by SERMS, branded bisphosphonates, and then denosumab and teriparatide, with some variations depending on the specific country. The ultimate selection of a specific pharmacologic treatment should take into account the patient's individual risk profile including the risk for a specific type of fractures (spine versus hip), co-morbid conditions, poly-pharmacy, and patient's preference. Finally, cost and cost-effectiveness considerations, insurance plans, and national health policies, will undoubtedly also modulate choice of therapeutic options.

PATIENTS AT HIGH RISK OF FRACTURE SHOULD DISCUSS LIFESTYLE INTERVENTIONS AND DRUG TREATMENT OPTIONS WITH THEIR DOCTORS.





# IMPORTANCE OF ADHERING TO TREATMENT

Like all medicines, osteoporosis treatments can only work if they are taken properly. As reported for other chronic diseases<sup>227-231</sup>, up to half of osteoporosis sufferers stop their treatment after only one year<sup>232</sup>. The primary reasons why individuals should adhere to treatment are:

- Larger increases in BMD will be achieved<sup>233</sup>.
- The amount of bone lost through the resorption process will be reduced<sup>234</sup>.
- Reduction of fracture risk is greater<sup>235</sup>.



## Eight tips to give patients to help them remain on treatment

1. Think about ways to take your medication (e.g. first thing in the morning before breakfast) in order to minimise the impact on your everyday life.
2. If you take regular pills for your osteoporosis, try to take your treatment at the same time each day, week or month.
3. Use a diary to remind yourself to take your medication and collect your prescription, or put a reminder somewhere you will see it frequently.
4. Make a note of the specific actions you need to remember when taking your treatment and keep this somewhere memorable.
5. Be prepared and plan for changes in your routine that will make it more difficult for you to take your medication, such as holidays or special events.
6. Ask your family and friends to support you to stay on treatment. Tell them about your medication and explain to them why it is important for you to continue to take it.
7. Speak to your health professional about difficulties you are experiencing. They will be able to give you advice on managing your osteoporosis medication and may be able to suggest other treatment options.
8. Contact your local patient society; they can offer you support and put you in touch with other people who are in a similar situation. You can also communicate with people who have osteoporosis on the OsteoLink social network site [www.osteolink.org](http://www.osteolink.org).

# REFERENCES

1. Australian Institute of Health and Welfare. Carers in Australia. Canberra, 2004.
2. Belasco A, Barbosa D, Bettencourt AR, Diccini S, Sesso R. Quality of life of family caregivers of elderly patients on hemodialysis and peritoneal dialysis. *Am J Kidney Dis.* Dec 2006;48(6):955-963.
3. Stobert S, Cranswick K. Looking after seniors: Who does what for whom? Ottawa, Ontario: Statistics Canada; 2004.
4. Kim SW, Kim JM, Stewart R, et al. Correlates of caregiver burden for Korean elders according to cognitive and functional status. *Int J Geriatr Psychiatry.* Sep 2006;21(9):853-861.
5. Martinez Lopez CR, Ramos del Rio B, Rendon MTR, Martinez Gonzalez LD, Lopez CGF. Burden and dependence in informal primary caregivers of severe cerebral palsy patients. *Psicologia y Salud.* 2012;22(2):275-282.
6. Mora HR, Mendoza RD, Avilés AGP. Quality of life of primary caregivers of geriatric patients from the Dr. Ignacio Chávez Family Medicine Clinic. *Revista de Especialidades Médico-Quirúrgicas.* 2011;16(1):27-32.
7. Gomez Blanco EI. The burden of primary caregiving for family with cancer. Veracruz, Mexico: Faculty of Nursing, University of Veracruz; 2008.
8. Pérez Ortiz L. Women as a resource for reconciling work and family life. Present and future. In: Ministerio de Empleo y Seguridad Social: Instituto de la Mujer - Rosa M. Peris, ed. Madrid, Spain; 2000.
9. Tang YY, Chen SP. Health promotion behaviors in Chinese family caregivers of patients with stroke. *Health Promot Int.* Dec 2002;17(4):329-339.
10. Huang CY, Sousa VD, Perng SJ, et al. Stressors, social support, depressive symptoms and general health status of Taiwanese caregivers of persons with stroke or Alzheimer's disease. *J Clin Nurs.* Feb 2009;18(4):502-511.
11. Equality and Human Rights Commission. How fair is Britain? Equality, Human Rights and Good Relations in 2010. The First Triennial Review. London, UK 2010.
12. Wootton JC. Women as caregivers. *J Womens Health.* Jun 1998;7(5):597-599.
13. Robert Wood Johnson Foundation, John Hopkins Bloomberg School of Public Health. Chronic Care: Making the Case for Ongoing Care. Princeton, NJ 2010.
14. DiGirolamo AM, Salgado de Snyder N. Women as primary caregivers in Mexico: challenges to well-being. *Salud Publica Mex.* Nov-Dec 2008;50(6):516-522.
15. Melton LJ, 3rd, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? *J Bone Miner Res.* Sep 1992;7(9):1005-1010.
16. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. *Osteoporos Int.* 2000;11(8):669-674.
17. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. *Bone.* Dec 2001;29(6):517-522.
18. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int.* Dec 2006;17(12):1726-1733.
19. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden: A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos.* [in press]. 2013.
20. International Osteoporosis Foundation. The Eastern European & Central Asian Regional Audit: Epidemiology, costs & burden of osteoporosis in 2010. 2010.
21. International Osteoporosis Foundation. The Middle East & Africa Regional Audit: Epidemiology, costs & burden of osteoporosis in 2011. 2011.
22. International Osteoporosis Foundation. The Asian Audit: Epidemiology, costs and burden of osteoporosis in Asia 2009. 2009.
23. Branigan T. China faces 'timebomb' of ageing population. *Guardian.* 20 March 2012, 2012.
24. Xia WB, He SL, Xu L, et al. Rapidly increasing rates of hip fracture in Beijing, China. *J Bone Miner Res.* Jan 2012;27(1):125-129.
25. International Osteoporosis Foundation. The Latin America Regional Audit: Epidemiology, costs & burden of osteoporosis in 2012. Nyon, Switzerland 2012.
26. National Bone Health Alliance. 2Million2Many. <http://www.2million2many.org/>. Accessed 3 July 2013.
27. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res.* Mar 2007;22(3):465-475.
28. Brauer CA, Coca-Perrillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. *JAMA.* Oct 14 2009;302(14):1573-1579.
29. Wright NC, Saag KG, Curtis JR, et al. Recent trends in hip fracture rates by race/ethnicity among older US adults. *J Bone Miner Res.* Nov 2012;27(11):2325-2332.
30. Jean S, O'Donnell S, Lagace C, et al. Trends in hip fracture rates in Canada: An age-period-cohort analysis. *J Bone Miner Res.* Jun 2013;28(6):1283-1289.
31. Leslie WD, O'Donnell S, Lagace C, et al. Population-based Canadian hip fracture rates with international comparisons. *Osteoporos Int.* Aug 2010;21(8):1317-1322.
32. Cooper C, Mitchell P, Kanis JA. Breaking the fragility fracture cycle. *Osteoporos Int.* Jul 2011;22(7):2049-2050.
33. Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020 (Global Burden of Disease and Injury Series). Harvard, MA; 1996.
34. Strom O, Borstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Arch Osteoporos.* Dec 2011;6(1-2):59-155.
35. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. *JAMA.* Jan 17 2001;285(3):320-323.
36. Clark P, Cons-Molina F, Deleze M, et al. The prevalence of radiographic vertebral fractures in Latin American countries: the Latin American Vertebral Osteoporosis Study (LAVOS). *Osteoporos Int.* Feb 2009;20(2):275-282.
37. Palacios S, Henderson VW, Sipes N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. *Climacteric.* Oct 2010;13(5):419-428.
38. Lanham-New SA. Importance of calcium, vitamin D and vitamin K for osteoporosis prevention and treatment. *Proc Nutr Soc.* May 2008;67(2):163-176.
39. Sambrook P, Kelly P, Eisman J. Bone mass and ageing. *Baillieres Clin Rheumatol.* Oct 1993;7(3):445-457.
40. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. *Trends Endocrinol Metab.* Nov 2012;23(11):576-581.
41. Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. *Lancet.* Feb 28 1981;1(8218):459-461.
42. Christiansen C, Christensen MS, Larsen NE, Transbol IB. Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. *J Clin Endocrinol Metab.* Dec 1982;55(6):1124-1130.
43. Richelson LS, Wahner HW, Melton LJ, 3rd, Riggs BL. Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. *N Engl J Med.* Nov 15 1984;311(20):1273-1275.
44. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. *Menopause Int.* Sep 2008;14(3):111-116.
45. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. *J Clin Oncol.* Jul 15 2001;19(14):3306-3311.
46. Rizzoli R, Body JJ, DeCensi A, et al. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper. *Osteoporos Int.* Nov 2012;23(11):2567-2576.
47. Rizzoli R, Body JJ, Brandi ML, et al. BONE IN CANCER: a Position Paper from the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease (in preparation); 2013.
48. Clark EM, Gould VC, Morrison L, Masud T, Tobias J. Determinants of fracture risk in a UK-population-based cohort of older women: a cross-sectional analysis of the Cohort for Skeletal Health in Bristol and Avon (COSHIBA). *Age Ageing.* Jan 2012;41(1):46-52.
49. Sambrook P, Cooper C. Osteoporosis. *Lancet.* Jun 17 2006;367(9527):2010-2018.
50. Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. *Osteoporos Int.* 2001;12(1):16-23.
51. Moayyeri A, Hammond CJ, Hart DJ, Spector TD. Effects of age on genetic influence on bone loss over 17 years in women: the Healthy Ageing Twin Study (HATS). *J Bone Miner Res.* Oct 2012;27(10):2170-2178.
52. Global Coalition on Aging. Welcome to the Global Coalition on Aging. <http://www.globalcoalitiononaging.com/>. Accessed 7 May 2013.
53. Pfeifer M, Sinaki M, Geusens P, et al. Musculoskeletal rehabilitation in osteoporosis: a review. *J Bone Miner Res.* Aug 2004;19(8):1208-1214.
54. Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. *J Bone Miner Res.* Jul 1992;7(7):761-769.
55. Chow R, Harrison JE, Notarius C. Effect of two randomised exercise programmes on bone mass of healthy postmenopausal women. *Br Med J (Clin Res Ed).* Dec 5 1987;295(6611):1441-1444.
56. Ebeling PR, Daly RM, Kerr DA, Kimlin MG. An evidence-informed strategy to prevent osteoporosis in Australia. *Med J Aust.* Feb 4 2013;198(2):90-91.
57. Martyn-St James M, Carroll S. Strength training combined with plyometric jumps in adults: sex differences in fat-bone axis adaptations. *J Appl Physiol.* Aug 2009;107(2):636; author reply 637.
58. Bonaïuti D, Shea B, Iovine R, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database of Systematic Reviews (Online).* 2002(3):CD000333.
59. Martyn-St James M, Carroll S. Meta-analysis of walking for preservation of bone mineral density in postmenopausal women. *Bone.* Sep 2008;43(3):521-531.
60. Marks R. Physical activity and hip fracture disability: a review. *J Aging Res.* 2011;2011:741918.
61. Hauer K, Rost B, Rutschke K, et al. Exercise training for rehabilitation and secondary prevention of falls in geriatric patients with a history of injurious falls. *J Am Geriatr Soc.* Jan 2001;49(1):10-20.
62. Li WC, Chen YC, Yang RS, Tsauo JY. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. *Clin Rehabil.* Oct 2009;23(10):888-896.
63. Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. *Arch Intern Med.* May 10 2010;170(9):813-820.
64. Campbell AJ, Robertson MC, Gardner MM, Norton RN, Tilyard MW, Buchner DM. Randomised controlled trial of a general practice programme of home based exercise to prevent falls in elderly women. *BMJ.* Oct 25 1997;315(7115):1065-1069.
65. International Osteoporosis Foundation. Exercise. <http://www.iofbonehealth.org/exercise>. Accessed 2 July 2013.
66. National Osteoporosis Foundation. Exercise for Strong Bones. <http://www.nof.org/articles/238>. Accessed 8 May 2013.
67. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. *Cochrane Database Syst Rev.* 2012;9:CD007146.
68. National Osteoporosis Foundation. Posture Exercises. <http://www.nof.org/articles/16>. Accessed 8 May 2013.
69. Pfeifer M, Minne HW. International Osteoporosis Foundation: Exercise recommendations. <http://www.iofbonehealth.org/exercise-recommendations>. Accessed 2 July 2013.
70. Carter ND, Khan KM, McKay HA, et al. Community-based exercise program reduces risk factors for falls in 65- to 75-year-old women with osteoporosis: randomized controlled trial. *CMAJ.* Oct 29 2002;167(9):997-1004.
71. Ekin JA, Sinaki M. Vertebral compression fractures sustained during golfing: report of three cases. *Mayo Clin Proc.* Jun 1993;68(6):566-570.
72. Sinaki M, Mikkelsen BA. Postmenopausal spinal osteoporosis: flexion versus extension exercises. *Arch Phys Med Rehabil.* Oct 1984;65(10):593-596.
73. Bullamore JR, Wilkinson R, Gallagher JC, Nordin BE, Marshall DH. Effect of age on calcium absorption. *Lancet.* Sep 12 1970;2(7672):535-537.
74. National Health and Medical Research Council. Nutrient Reference Values for Australia and New Zealand including Recommended Dietary Intakes 2006.
75. Osteoporosis Canada. Calcium: An Important Nutrient that Builds Stronger Bones. <http://www.osteoporosis.ca/osteoporosis-and-you/nutrition/calcium-requirements/>. Accessed 2 July 2013.
76. Korean Nutrition Society. Korean Nutrition Society website. <http://www.kns.or.kr/>. Accessed 2 July 2013.
77. Department of Health. Vitamins and minerals - Calcium. <http://www.nhs.uk/Conditions/vitamins-minerals/Pages/Calcium.aspx>. Accessed 2 July 2013.
78. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D 2010.
79. WHO/FAO. Chapter 11. Calcium - Recommendations by group. <http://www.fao.org/docrep/004/Y2809E/y2809e0h.htm#bm17.7>. Accessed 2 July 2013.
80. Australian Bureau of Statistics. Australian Department of Health and Aged Care. National nutrition survey : nutrient intakes and physical measurements, Australia, 1995, 1998.
81. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med.* Apr 1 1997;126(7):497-504.
82. Wallace RB, Wactawski-Wende J, O'Sullivan MJ, et al. Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements. *Am J Clin Nutr.* Jul 2011;94(1):270-277.
83. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med.* Mar 25 1993;328(12):833-838.
84. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. *BMJ.* Feb 2 2008;336(7638):262-266.



85. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. *BMJ*. 2010;341:c3691.
86. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow WH, Park Y. Dietary and Supplemental Calcium Intake and Cardiovascular Disease Mortality: The National Institutes of Health-AARP Diet and Health Study. *JAMA Intern Med*. Apr 22 2013;173(8):639-646.
87. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. *Circulation*. Feb 20 2007;115(7):846-854.
88. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. *J Bone Miner Res*. Jan 2011;26(1):35-41.
89. Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. *J Clin Endocrinol Metab*. Aug 2012;97(8):2670-2681.
90. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. *Osteoporos Int*. Jul 2010;21(7):1151-1154.
91. Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzon L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. *JAMA*. Nov 9 2005;294(18):2336-2341.
92. Bischoff-Ferrari HA, Kiel DP, Dawson-Hughes B, et al. Dietary calcium and serum 25-hydroxyvitamin D status in relation to BMD among U.S. adults. *J Bone Miner Res*. May 2009;24(5):935-942.
93. Joo NS, Dawson-Hughes B, Kim YS, Oh K, Yeum KI. Impact of calcium and vitamin D insufficiencies on serum parathyroid hormone and bone mineral density: analysis of the fourth and fifth Korea National Health and Nutrition Examination Survey (KNHANES IV-3, 2009 and KNHANES V-1, 2010). *J Bone Miner Res*. Apr 2013;28(4):764-770.
94. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. <http://www.cdc.gov/nchs/nhanes/nh3data.htm>. Accessed 2 July 2013.
95. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. *J Bone Miner Res*. Jun 2000;15(6):1113-1118.
96. Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H. Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. *Osteoporos Int*. Feb 2009;20(2):315-322.
97. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. *BMJ*. 2009;339:b3692.
98. Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: The effect of vitamin D on falls: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. Oct 2011;96(10):2997-3006.
99. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. Jul 2011;96(7):1911-1930.
100. Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. *Osteoporos Int*. Nov 2009;20(11):1807-1820.
101. Heaney RP, Davies KM, Chen TC, Holick MF, Berger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr*. Jan 2003;77(1):204-210.
102. Houston DK, Nicklas BJ, Ding J, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. *Am J Clin Nutr*. Jan 2008;87(1):150-155.
103. Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. *J Bone Miner Res*. Dec 2000;15(12):2504-2512.
104. Dawson-Hughes B, Harris SS. Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women. *Am J Clin Nutr*. Apr 2002;75(4):773-779.
105. Frassetto LA, Morris RC, Jr, Sebastian A. Effect of age on blood acid-base composition in adult humans: role of age-related renal functional decline. *Am J Physiol*. Dec 1996;271(6 Pt 2):F114-1122.
106. Ludwig MG, Vanek M, Guerini D, et al. Proton-sensing G-protein-coupled receptors. *Nature*. Sep 4 2003;425(6953):93-98.
107. Tomura H, Mogi C, Sato K, Okajima F. Proton-sensing and lysolipid-sensitive G-protein-coupled receptors: a novel type of multi-functional receptors. *Cell Signal*. Dec 2005;17(12):1466-1476.
108. Frick KK, Krieger NS, Nehrke K, Bushinsky DA. Metabolic acidosis increases intracellular calcium in bone cells through activation of the proton receptor OGR1. *J Bone Miner Res*. Feb 2009;24(2):305-313.
109. Arnett TR, Dempster DW. Effect of pH on bone resorption by rat osteoclasts in vitro. *Endocrinology*. Jul 1986;119(1):119-124.
110. Komarova SV, Pereverzev A, Shum JW, Sims SM, Dixon SJ. Convergent signaling by acidosis and receptor activator of NF-kappaB ligand (RANKL) on the calcium/calciuretin/NFAT pathway in osteoclasts. *Proc Natl Acad Sci U S A*. Feb 15 2005;102(7):2643-2648.
111. Bushinsky DA. Metabolic alkalosis decreases bone calcium efflux by suppressing osteoclasts and stimulating osteoblasts. *Am J Physiol*. Jul 1996;271(1 Pt 2):F216-222.
112. Tucker KL, Chen H, Hannan MT, et al. Bone mineral density and dietary patterns in older adults: the Framingham Osteoporosis Study. *Am J Clin Nutr*. Jul 2002;76(1):245-252.
113. Jones G, Riley MD, Whiting S. Association between urinary potassium, urinary sodium, current diet, and bone density in prepubertal children. *Am J Clin Nutr*. Apr 2001;73(4):839-844.
114. New SA, Bolton-Smith C, Grubb DA, Reid DM. Nutritional influences on bone mineral density: a cross-sectional study in premenopausal women. *Am J Clin Nutr*. Jun 1997;65(6):1831-1839.
115. Chen Y, Ho SC, Lee R, Lam S, Woo J. Fruit intake is associated with better bone mass among Hong Kong Chinese early postmenopausal women. *J Bone Miner Res*. 2001;16(Suppl 1):S386.
116. Macdonald HM, New SA, Golden MH, Campbell MK, Reid DM. Nutritional associations with bone loss during the menopausal transition: evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids. *Am J Clin Nutr*. Jan 2004;79(1):155-165.
117. Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. *Osteoporos Int*. Feb 2005;16(2):155-162.
118. Hayatbakhsh MR, Clavarino A, Williams GM, Sina M, Najman JM. Cigarette smoking and age of menopause: a large prospective study. *Maturitas*. Aug 2012;72(4):346-352.
119. Albanes D, Jones DY, Micozzi MS, Mattson ME. Associations between smoking and body weight in the US population: analysis of NHANES II. *Am J Public Health*. Apr 1987;77(4):439-444.
120. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. *N Engl J Med*. Nov 20 1986;315(21):1305-1309.
121. Laitinen K, Valimaki M, Keto P. Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women. *Calcif Tissue Int*. Apr 1991;48(4):224-231.
122. Marrone JA, Maddalozzo GF, Branscum AJ, et al. Moderate alcohol intake lowers biochemical markers of bone turnover in postmenopausal women. *Menopause*. Sep 2012;19(9):974-979.
123. Felson DT, Kiel DP, Anderson JJ, Kannel WB. Alcohol consumption and hip fractures: the Framingham Study. *Am J Epidemiol*. Nov 1988;128(5):1102-1110.
124. Laitinen K, Valimaki M. Alcohol and bone. *Calcif Tissue Int*. 1991;49 Suppl:S70-73.
125. Dymally JF, Ljungberg O, Hilliard CJ, Greenberg PB, Evans IM, MacIntyre I. Whisky: a new provocative test for calcitonin secretion. *Acta Endocrinol (Copenh)*. Jul 1976;82(3):500-509.
126. Rico H. Alcohol and bone disease. *Alcohol Alcohol*. 1990;25(4):345-352.
127. Malmivaara A, Heliövaara M, Knekt P, Reunanen A, Aromaa A. Risk factors for injurious falls leading to hospitalization or death in a cohort of 19,500 adults. *Am J Epidemiol*. Sep 15 1993;138(6):384-394.
128. Gunnes M, Mellstrom D, Johnell O. How well can a previous fracture indicate a new fracture? A questionnaire study of 29,802 postmenopausal women. *Acta Orthop Scand*. Oct 1998;69(5):508-512.
129. Ensrud KE, Nevitt MC, Yunis C, et al. Correlates of impaired function in older women. *J Am Geriatr Soc*. May 1994;42(5):481-489.
130. Nelson HD, Nevitt MC, Scott JC, Stone KL, Cummings SR. Smoking, alcohol, and neuromuscular and physical function of older women. Study of Osteoporotic Fractures Research Group. *JAMA*. Dec 21 1994;272(23):1825-1831.
131. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. *Osteoporos Int*. Nov 2005;16(11):1330-1338.
132. Wolfert A, Mehler PS. Osteoporosis: prevention and treatment in anorexia nervosa. *Eat Weight Disord*. Jun 2002;7(2):72-81.
133. Malnutrition Task Force. Malnutrition The Facts. <http://www.malnutritiontaskforce.org.uk/malnutrition-the-facts.html>. Accessed 2 July 2013.
134. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res*. Apr 2000;15(4):721-739.
135. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. *Bone*. Aug 2004;35(2):375-382.
136. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. *Clin Orthop Relat Res*. Aug 2007;461:226-230.
137. Gallagher JC, Melton LJ, Riggs BL, Bergstrath E. Epidemiology of fractures of the proximal femur in Rochester, Minnesota. *Clin Orthop Relat Res*. Jul-Aug 1980(150):163-171.
138. McLellan A, Reid D, Forbes K, et al. Effectiveness of Strategies for the Secondary Prevention of Osteoporotic Fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland; 2004.
139. Port L, Center J, Briffa NK, Nguyen T, Cumming R, Eisman J. Osteoporotic fracture: missed opportunity for intervention. *Osteoporos Int*. Sep 2003;14(9):780-784.
140. Marsh D, Akesson K, Beaton DE, et al. Coordinator-based systems for secondary prevention in fragility fracture patients. *Osteoporos Int*. Jul 2011;22(7):2051-2065.
141. Mitchell PJ. Fracture Liaison Services: the UK experience. *Osteoporos Int*. Aug 2011;22 Suppl 3:487-494.
142. International Osteoporosis Foundation. Post-fracture care gap. <http://www.capturethefracture.org/post-fracture-care-gap>. Accessed 2 July 2013.
143. Akesson K, Mitchell P. Capture the Fracture: A global campaign to break the fragility fracture cycle. Nyon, Switzerland: International Osteoporosis Foundation; 2012.
144. Akesson K, Marsh D, Mitchell PJ, et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. *Osteoporos Int*. Apr 16 2013.
145. Arden NK, Baker J, Hogg C, Baan K, Spector TD. The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins. *J Bone Miner Res*. Apr 1996;11(4):530-534.
146. Gueguen R, Jouanny P, Guillemin F, Kuntz C, Porel J, Siest G. Segregation analysis and variance components analysis of bone mineral density in healthy families. *J Bone Miner Res*. Dec 1995;10(12):2017-2022.
147. Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S. Genetic determinants of bone mass in adults. A twin study. *J Clin Invest*. Sep 1987;80(3):706-710.
148. Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. *Bone*. Nov 2004;35(5):1029-1037.
149. Bonewald LF. The amazing osteocyte. *J Bone Miner Res*. Feb 2011;26(2):229-238.
150. Angeli A, Guglielmi G, Dovic A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. *Bone*. Aug 2006;39(2):253-259.
151. O'Neill TW, Felsenberg D, Varlow J, Cooper C, Kanis JA, Silman AJ. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. *J Bone Miner Res*. Jul 1996;11(7):1010-1018.
152. Carppinteri R, Porcelli T, Mejia C, et al. Glucocorticoid-induced osteoporosis and parathyroid hormone. *J Endocrinol Invest*. 2010;33(7 Suppl):16-21.
153. Adachi JD, Saag KG, Delmas PD, et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. *Arthritis Rheum*. Jan 2001;44(1):202-211.
154. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. *European Corticosteroid-Induced Osteoporosis Treatment Study*. *J Bone Miner Res*. Jun 2000;15(6):1006-1013.
155. Nawata H, Soen S, Takayanagi R, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). *J Bone Miner Metab*. 2005;23(2):105-109.
156. Compston J. US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences. *Curr Rheumatol Rep*. Feb 2004;6(1):66-69.
157. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. *Ann Rheum Dis*. Jan 2002;61(1):32-36.
158. Ramsey-Goldman R. Missed opportunities in physician management of glucocorticoid-induced osteoporosis? *Arthritis Rheum*. Dec 2002;46(12):3115-3120.
159. Schoon EJ, van Nunen AB, Wouters RS, Stockbrugger RW, Russel MG. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. *Scand J Gastroenterol Suppl*. 2000(232):43-47.
160. Siffledeen JS, Fedorak RN, Siminoski K, et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. *Inflamm Bowel Dis*. May 2004;10(3):220-228.
161. Stazi AV, Trecca A, Trinti B. Osteoporosis in celiac disease and in endocrine and reproductive disorders. *World J Gastroenterol*. Jan 28 2008;14(4):498-505.
162. Lewis NR, Scott BB. Guidelines for osteoporosis in inflammatory bowel disease and coeliac disease. London: British Society of Gastroenterology; 2007.
163. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. *Osteoporos Int*. Jun 2005;16(6):581-589.
164. Orstavik RE, Haugeberg G, Uhlig T, et al. Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. *Osteoporos Int*. Jan 2005;16(1):35-42.



165. Broy SB, Tanner SB, Members FRDC. Official Positions for FRAX(R) clinical regarding rheumatoid arthritis from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). *J Clin Densitom.* Jul-Sep 2011;14(3):184-189.
166. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. *Ann Rheum Dis.* Dec 2004;63(12):1576-1580.
167. Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. *Maturitas.* Feb 2010;65(2):161-166.
168. Gallagher JC. Effect of early menopause on bone mineral density and fractures. *Menopause.* May-Jun 2007;14(3 Pt 2):567-571.
169. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. *Osteoporos Int.* 1997;7(4):390-406.
170. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. *Arch Intern Med.* May 24 2004;164(10):1108-1112.
171. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. *J Bone Miner Res.* Oct 2005;20(10):1813-1819.
172. Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. *Osteoporos Int.* 2006;17(9):1404-1409.
173. Osteoporosis Research in partnership with International Osteoporosis Foundation. How fragile is her future? A report investigating the current understanding and management of osteoporosis around the world today. Nyon, Switzerland 2000.
174. Bischoff-Ferrari HA. Three steps to unbreakable bones: Vitamin D, Calcium and Exercise. Nyon, Switzerland: International Osteoporosis Foundation; 2011.
175. Cauley JA, El-Hajj Fuleihan G, Arabi A, et al. Official Positions for FRAX(R) clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). *J Clin Densitom.* Jul-Sep 2011;14(3):240-262.
176. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. *Osteoporos Int.* Apr 2008;19(4):385-397.
177. Kanis JA, Hans D, Cooper C, et al. Interpretation and use of FRAX in clinical practice. *Osteoporos Int.* Sep 2011;22(9):2395-2411.
178. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. *Osteoporos Int.* Aug 2007;18(8):1033-1046.
179. Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. *Endocr Pract.* Nov-Dec 2010;16 Suppl 3:1-37.
180. Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ.* Nov 23 2010;182(17):1864-1873.
181. Hans DB, Kanis JA, Baim S, et al. Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(R). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX(R) in clinical practice. *J Clin Densitom.* Jul-Sep 2011;14(3):171-180.
182. National Osteoporosis Foundation. NOF's Newly Revised 2013 Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington D.C., USA 2013.
183. Briot K, Cortet B, Thomas T, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. *Joint Bone Spine.* May 2012;79(3):304-313.
184. National Osteoporosis Guideline Group. Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK 2013.
185. Schurman L, Bagur A, Claus-Hermberg H, et al. [Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012]. *Medicina (B Aires).* 2013;73(1):55-74.
186. El-Hajj Fuleihan G, El-Kak F. FRAX Based Lebanese Osteoporosis Guidelines: Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment (publication pending). Lebanese Society for Osteoporosis and Metabolic Bone Disorders; 2013.
187. ClinRisk. Welcome to the QFracture®-2012 risk calculator. [http://www.qfracture.org](http://qfracture.org). Accessed 3 July 2013.
188. Garvan Institute. FFracture Risk Calculator. <http://garvan.org.au/promotions/bone-fracture-risk-calculator/>. Accessed 3 July 2013.
189. International Society for Fracture Repair. Osteoporotic Fracture Campaign. [http://www.fractures.com/about\\_ofc.html](http://www.fractures.com/about_ofc.html). Accessed 3 July 2013.
190. Fragility Fracture Network. FFN - A Global Network to Improve Fragility Fracture Management and Prevention. <http://www.ff-network.org/>. Accessed 3 July 2013.
191. The Bone and Joint Decade Global Alliance for Musculoskeletal Health. Prevention and Control. [http://bjdonline.org/?page\\_id=111](http://bjdonline.org/?page_id=111). Accessed 3 July 2013.
192. Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. In: US Department of Health and Human Services, ed. Washington; 2004.
193. Eisman JA, Bogoch ER, Dell R, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. *J Bone Miner Res.* Oct 2012;27(10):2039-2046.
194. National Bone Health Alliance. Fracture Prevention CENTRAL. <http://www.nbha.org/fpc>. Accessed 20 May 2013.
195. American Academy of Orthopaedic Surgeons, American Association of Orthopaedic Surgeons. Position Statement: Recommendations for Enhancing the Care of Patients with Fragility Fractures. <http://www.aaos.org/about/papers/position/1159.asp>. Accessed 10 December 2012.
196. Osteoporosis Canada. Osteoporosis: Towards a fracture free future. Toronto 2011.
197. New South Wales Agency for Clinical Innovation Musculoskeletal Network. NSW Model of Care for Osteoporotic Refracture Prevention. Chatswood, NSW; 2011.
198. Statewide Orthopaedic Clinical Network and Rehabilitation Clinical Network. Models of Care for Orthopaedic Rehabilitation - Fragility Fractures General Orthopaedic Trauma and Arthroplasty. In: Government of South Australia, SA Health, eds. Adelaide; 2011.
199. Government of Western Australia. Osteoporosis Model of Care. In: Department of Health Musculoskeletal Diabetes & Endocrine Falls Prevention and Aged Care Health Networks (WA), ed. Perth; 2011.
200. Osteoporosis New Zealand. Bone Care 2020: A systematic approach to hip fracture care and prevention for New Zealand. Wellington 2012.
201. Australian and New Zealand Hip Fracture Registry. Australian and New Zealand Hip Fracture Registry website. <http://www.anzhfr.org/>. Accessed 21 December 2012.
202. British Orthopaedic Association, British Geriatrics Society. The care of patients with fragility fracture 2007.
203. British Orthopaedic Association, British Geriatrics Society, Healthcare Quality Improvement Partnership. The National Hip Fracture Database. <http://www.nhfd.co.uk/>. Accessed 15 March 2012.
204. Department of Health. Falls and fractures: Effective interventions in health and social care. In: Department of Health, ed; 2009.
205. Department of Health. Fracture prevention services: an economic evaluation.; 2009.
206. National Osteoporosis Society. The Falls and Fractures Declaration. <http://www.nos.org.uk/page.aspx?pid=1248>. Accessed 1 November 2012.
207. National Osteoporosis Society. Protecting fragile bones: A strategy to reduce the impact of osteoporosis and fragility fractures in England/Scotland/Wales/Northern Ireland May-Jun 2009 2009.
208. Swiss Association Against Osteoporosis. Recommendations 2010: Prevention, diagnosis, treatment; 2010.
209. Briot K, Cortet B, Thomas T, et al. 2012 French updated recommendations for the drug treatment of postmenopausal osteoporosis. *Revue du Rhumatisme.* 2012;79(3):264-274.
210. National Osteoporosis Guideline Group. What is NOGG? <http://www.shef.ac.uk/NOGG/>. Accessed 3 July 2013.
211. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD. FRAX(R) with and without bone mineral density. *Calcif Tissue Int.* Jan 2012;90(1):1-13.
212. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. *Bone.* Oct 2010;47(4):729-735.
213. McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. *J Bone Miner Res.* Jul 2012;27(7):1480-1486.
214. McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. *Osteoporos Int.* May 2009;20(5):811-817.
215. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int.* Jan 2013;24(1):23-57.
216. Khosla S, Bilezikian JP, Dempster DW, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. *J Clin Endocrinol Metab.* Jul 2012;97(7):2272-2282.
217. Uihlein AV, Leder BZ. Anabolic therapies for osteoporosis. *Endocrinol Metab Clin North Am.* Sep 2012;41(3):507-525.
218. Diab DL, Watts NB. Bisphosphonates in the treatment of osteoporosis. *Endocrinol Metab Clin North Am.* Sep 2012;41(3):487-506.
219. Bone H. Future directions in osteoporosis therapeutics. *Endocrinol Metab Clin North Am.* Sep 2012;41(3):655-661.
220. Cusano NE, Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis. *Endocrinol Metab Clin North Am.* Sep 2012;41(3):643-654.
221. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? *N Engl J Med.* May 31 2012;366(22):2048-2051.
222. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? *N Engl J Med.* May 31 2012;366(22):2051-2053.
223. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. *JAMA.* Jul 17 2002;288(3):321-333.
224. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA.* Apr 14 2004;291(14):1701-1712.
225. Clinicaltrials.gov. Kronos Early Estrogen Prevention Study (KEEPS). <http://clinicaltrials.gov/ct2/show/NCT00154180>. Accessed 3 July 2013.
226. Wolff EF, He Y, Black DM, et al. Self-reported menopausal symptoms, coronary artery calcification, and carotid intima-media thickness in recently menopausal women screened for the Kronos early estrogen prevention study (KEEPS). *Fertil Steril.* Apr 2013;99(5):1385-1391.
227. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. *Arch Intern Med.* Apr 12 2004;164(7):722-732.
228. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. *Clin Ther.* Dec 2001;23(12):1999-2010.
229. Cramer JA. A systematic review of adherence with medications for diabetes. *Diabetes Care.* May 2004;27(5):1218-1224.
230. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. *JAMA.* Jul 24-31 2002;288(4):455-461.
231. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. *JAMA.* Jul 24-31 2002;288(4):462-467.
232. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. *Osteoporos Int.* Jun 2007;18(6):711-719.
233. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. *Am J Med.* Aug 15 2003;115(3):209-216.
234. Seibaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A. Long-term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. *Osteoporos Int.* 2004;15:107 [Abstract P3915A].
235. Olsen KR, Hansen C, Abrahamsen B. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. *Osteoporos Int.* Apr 20 2013.

*Bone loss accelerates at menopause, making women over 50 particularly susceptible to the potentially devastating effects of osteoporosis and fractures. No matter what your age, strategies for prevention should include a combination of targeted exercise, bone-healthy nutrition, avoidance of negative lifestyle factors, and early identification of individual risk factors. Take action today to maintain strong bones and muscles that will carry you through a lifetime.*

**PROF CYRUS COOPER**  
Chair of the Committee of  
Scientific Advisors, IOF

#### World Osteoporosis Day 2013 Sponsors



**AUTHORS** **Bess Dawson-Hughes** Tufts University, USA  
**Ghada El-Hajj Fuleihan** American University of Beirut, Lebanon  
**Patricia Clark** National University of Mexico  
**EDITORS** **Paul Mitchell** Synthesis Medical Limited and University of Derby, UK  
**Laura Misteli** IOF  
**REVIEWERS** **Prof Cyrus Cooper, Dr Mark Edwards, Dr Nick Harvey**  
MRC Lifecourse Epidemiology Unit, University of Southampton, UK  
**DESIGN** **Gilberto D Lontro** IOF

WorldOsteoporosisDay | LOVE YOUR  
October20 BONES

**International Osteoporosis Foundation**  
rue Juste-Olivier, 9 • CH-1260 Nyon  
Switzerland  
**T** +41 22 994 01 00 **F** +41 22 994 01 01  
info@iofbonehealth.org  
[www.iofbonehealth.org](http://www.iofbonehealth.org)

COVER PHOTO **SERGEY NIVENS**